NASDAQ:KZIA
Kazia Therapeutics Limited Stock News
$0.260
+0.0103 (+4.12%)
At Close: May 31, 2024
Kazia wins ANZLF Trans-Tasman Innovation & Growth Award and reports new data from clinical trial in childhood brain cancer
12:00pm, Friday, 13'th Sep 2019
SYDNEY, Sept. 13, 2019 /PRNewswire/ -- Australian oncology-focused biotech company Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) is pleased to announce that it has been named as a winner in the 2019
St Jude Study of GDC-0084 in DIPG Successfully Completes First Stage; Second Part of Study Now Underway
01:10pm, Thursday, 12'th Sep 2019
NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that St Jude Children's Research Hospital has successfully completed the first stage of its ongoing phase I
Kazia to test GDC-0084 with Radiotherapy in Phase I Clinical Trial at Leading US Cancer Center
01:00pm, Monday, 22'nd Jul 2019
NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that Memorial Sloan Kettering Cancer Center (MSK) in New York, NY will investigate the potential use of Kazi
Kazia calls for greater awareness of the deadliest brain cancer in the US
12:00pm, Wednesday, 17'th Jul 2019
SYDNEY , July 17, 2019 /PRNewswire/ -- T his Glioblastoma Awareness Day, Australian oncology-focused biotech company, Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA), calls for greater awareness of
